- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06995417
- Original Trial
Discontinuation of Tobacco Dependence in Smoking Patients With Squamous Cell Carcinoma of the Head-neck District: Multicenter Prospective Observational Study (STOP-HNC)
May 26, 2025 updated by: Lorenzo Livi, Azienda Ospedaliero-Universitaria Careggi
The primary objective of our study is to evaluate the effectiveness of a standardized clinical practice counseling strategy for promoting post-diagnosis smoking cessation among patients with SCCHN.
Efficacy will be measured as the percentage of patients who succeed in sustained smoking cessation ("sustained quitters," see below) at 6+1 months after enrollment, i.e., after the initiation of anti-smoking counseling.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: PIERLUIGI PB BONOMO, MEDICAL DOCTOR
- Phone Number: +390557947010
- Email: bonomopierlu@gmail.com
Study Contact Backup
- Name: LUCIA PAOLINI
- Phone Number: +393393830695
- Email: rt.datamanager@sbsc.unifi.it
Study Locations
-
-
Firenze
-
Florence, Firenze, Italy, 51134
- Azienda Ospedaliera Careggi
-
Contact:
- LORENZO LIVI
- Phone Number: +390557947019
- Email: lorenzo.livi@unifi.it
-
Sub-Investigator:
- Pierluigi Bonomo, MEDICAL DOCTOR
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The study population will be patients with SCCHN who are active smokers, or have quit smoking for less than 30 days, at the time of initiation of the process (visits and instrumental examinations) that led to the cancer diagnosis
Description
Inclusion criteria.
- Patients with SCCHN tumors of the oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, and paranasal sinuses.
- Patients older than 18 years of age with SCCHN of these sites who are candidates for surgical/radiotherapy (RT)/radiochemotherapy (RTCT) treatment with curative intent (primary treatment).
- Patients with SCCHN who are active smokers, or have quit smoking for less than 30 days, at the time of initiation of the process (visits and instrumental tests) that led to the diagnosis of cancer
Exclusion criteria
- Patients with SCCHN cancer who have quit smoking for more than 30 days at the time of initiation of the diagnostic process.
- Patients using only e-cigarettes at the time of initiation of the treatment process.
- Patients with non-SCCHN cancer in recurrent metastatic stage and not eligible for curative purpose therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effectiveness of a standardized counseling strategy in clinical practice to promote smoking cessation
Time Frame: 6+1 months from enrollment, i.e., initiation of anti-smoking counseling.
|
The primary objective of our study is to evaluate the effectiveness of a standardized clinical practice counseling strategy for promoting post-diagnosis smoking cessation among patients with SCCHN.
Efficacy will be measured as the percentage of patients who succeed in sustained smoking cessation ("sustained quitters," see below) at 6+1 months after enrollment, i.e., after the initiation of anti-smoking counseling.
|
6+1 months from enrollment, i.e., initiation of anti-smoking counseling.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: LORENZO LL LIVI, MEDICAL DOCTOR, Aou Careggi
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2025
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
May 1, 2030
Study Registration Dates
First Submitted
March 31, 2025
First Submitted That Met QC Criteria
May 26, 2025
First Posted (Actual)
May 29, 2025
Study Record Updates
Last Update Posted (Actual)
May 29, 2025
Last Update Submitted That Met QC Criteria
May 26, 2025
Last Verified
May 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STOP-HNC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.